Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week

Trial Profile

Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Pantoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 04 May 2012 Company (Takeda Global Research and Development Center) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 20 Sep 2006 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top